The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | Impact of melphalan dose combined with fludarabine on GI toxicity & GvHD after alloSCT in AML/MDS
Nelli Bejanyan, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses the findings of a study assessing the impact of melphalan dose in combination with fludarabine on gastrointestinal (GI) toxicity and graft-versus-host disease (GvHD) after allogeneic stem cell transplantation (alloSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Dr Bejanyan notes that patients who received the lower dose of melphalan had a reduced risk of GI toxicities and acute GvHD compared to those who received the higher dose, without relapse or survival outcomes being negatively affected. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So sure, I’m happy to discuss the abstract that we are presenting, comparing two commonly used doses of melphalan, 100 mg per meter squared to 140 mg per meter squared in combination with fludarabine, which is a common reduced intensity conditioning regimen used for transplantation in older patients with myeloid malignancies, including acute leukemia.
So what we found in this study was that patients who received 100 milligram dose of melphalan in comparison to 140 milligram dose in combination with fludarabine, they had lower risk of GI toxicities as well as acute graft-versus-host disease...
So sure, I’m happy to discuss the abstract that we are presenting, comparing two commonly used doses of melphalan, 100 mg per meter squared to 140 mg per meter squared in combination with fludarabine, which is a common reduced intensity conditioning regimen used for transplantation in older patients with myeloid malignancies, including acute leukemia.
So what we found in this study was that patients who received 100 milligram dose of melphalan in comparison to 140 milligram dose in combination with fludarabine, they had lower risk of GI toxicities as well as acute graft-versus-host disease. But this didn’t translate into affecting other outcomes such as, for example, relapse and survival outcomes as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy or advisory role: CareDx, Medexus Pharmaceuticals, ORCA Biosystems, AlloVir, TScan Therapeutics, Pfizer; Research funding: CRISPR Therapeutics.
